Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.


Journal

American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369

Informations de publication

Date de publication:
05 2023
Historique:
revised: 07 02 2023
received: 30 11 2022
accepted: 20 02 2023
medline: 12 4 2023
pubmed: 24 2 2023
entrez: 23 2 2023
Statut: ppublish

Résumé

Myeloproliferative neoplasms (MPN) are characterized by uncontrolled expansion of myeloid cells, disease-related mutations in certain driver-genes including JAK2, CALR, and MPL, and a substantial risk to progress to secondary acute myeloid leukemia (sAML). Although behaving as stem cell neoplasms, little is known about disease-initiating stem cells in MPN. We established the phenotype of putative CD34

Identifiants

pubmed: 36814396
doi: 10.1002/ajh.26889
doi:

Substances chimiques

Calreticulin 0
dBET6 0
Janus Kinase 2 EC 2.7.10.2
Nuclear Proteins 0
Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

770-783

Informations de copyright

© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.

Références

N Engl J Med. 2006 Dec 7;355(23):2452-66
pubmed: 17151367
Blood. 2017 Jul 27;130(4):397-407
pubmed: 28576879
Blood. 2019 Jul 11;134(2):199-210
pubmed: 31064751
Exp Hematol. 2015 Aug;43(8):599-608
pubmed: 26209551
Immunol Rev. 1991 Dec;124:25-43
pubmed: 1804779
Nature. 1994 Feb 17;367(6464):645-8
pubmed: 7509044
Cell. 2009 Jul 23;138(2):286-99
pubmed: 19632179
Int J Mol Sci. 2021 Jan 11;22(2):
pubmed: 33440869
J Natl Compr Canc Netw. 2015 Apr;13(4):424-34
pubmed: 25870379
Am J Hematol. 2022 Apr;97(4):390-400
pubmed: 35015307
Leukemia. 2021 Nov;35(11):3176-3187
pubmed: 33785864
Cancer Discov. 2021 Dec 1;11(12):3126-3141
pubmed: 34193440
Blood. 2008 Aug 1;112(3):568-75
pubmed: 18523148
Leukemia. 2016 May;30(5):1018-24
pubmed: 26854026
Am J Hematol. 2016 Jan;91(1):50-8
pubmed: 26492355
Leuk Res. 2016 Sep;48:11-5
pubmed: 27427771
Stem Cells Transl Med. 2020 Nov;9(11):1331-1343
pubmed: 32657052
Curr Hematol Malig Rep. 2019 Aug;14(4):310-327
pubmed: 31228096
Leukemia. 2005 Mar;19(3):435-41
pubmed: 15674418
Blood. 2007 Oct 1;110(7):2659-66
pubmed: 17609428
Blood Cancer J. 2018 Feb 9;8(2):15
pubmed: 29426921
Hematol Oncol. 2019 Aug;37(3):240-252
pubmed: 31013548
Blood. 2021 Apr 8;137(14):1920-1931
pubmed: 33202418
Leukemia. 2008 Oct;22(10):1841-8
pubmed: 18754034
Blood. 2017 Feb 9;129(6):680-692
pubmed: 28028026
Leukemia. 2022 Jul;36(7):1703-1719
pubmed: 35732831
Leuk Res. 2015 Apr;39(4):419-23
pubmed: 25687833
Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16280-5
pubmed: 20805474
Leukemia. 2018 May;32(5):1057-1069
pubmed: 29515238
Am J Hematol. 2023 May;98(5):770-783
pubmed: 36814396
Exp Hematol. 2017 Jul;51:17-24
pubmed: 28457753
Sci Transl Med. 2010 Feb 3;2(17):17ra9
pubmed: 20371479
Nat Med. 1997 Jul;3(7):730-7
pubmed: 9212098
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11008-13
pubmed: 17576927
N Engl J Med. 2004 Aug 12;351(7):657-67
pubmed: 15306667
Leukemia. 2009 Jan;23(1):25-42
pubmed: 18800146
Exp Hematol. 2007 Nov;35(11):1633-40
pubmed: 17764815
Blood. 2016 Jun 30;127(26):3398-409
pubmed: 27114459
Trends Mol Med. 2007 Nov;13(11):470-81
pubmed: 17981087
N Engl J Med. 2007 Feb 1;356(5):459-68
pubmed: 17267906
Eur J Haematol. 2014 Apr;92(4):289-97
pubmed: 24372927
Biol Blood Marrow Transplant. 2015 Nov;21(11):1883-7
pubmed: 26371371
Cell Rep. 2017 Feb 28;18(9):2162-2174
pubmed: 28249162
J Clin Invest. 2012 Nov;122(11):3888-99
pubmed: 23023702
Blood. 2017 Feb 9;129(6):667-679
pubmed: 28028029
Curr Cancer Drug Targets. 2011 Jan;11(1):56-71
pubmed: 21062243
Sci Transl Med. 2018 Feb 21;10(429):
pubmed: 29467301
J Clin Oncol. 2008 Jun 10;26(17):2911-5
pubmed: 18539972
Neoplasia. 2018 Jun;20(6):632-642
pubmed: 29772458
Curr Hematol Malig Rep. 2009 Apr;4(2):66-73
pubmed: 20425417
Cancers (Basel). 2020 Apr 21;12(4):
pubmed: 32326377
Blood Adv. 2017 Jun 13;1(14):972-979
pubmed: 29296739
Blood. 2008 Sep 15;112(6):2429-38
pubmed: 18612101
N Engl J Med. 2017 Jun 1;376(22):2168-2181
pubmed: 28564565
Blood Adv. 2020 Jun 9;4(11):2477-2488
pubmed: 32502268
Cancers (Basel). 2020 Dec 12;12(12):
pubmed: 33322769
Biol Blood Marrow Transplant. 2017 Sep;23(9):1429-1436
pubmed: 28499938
Semin Hematol. 1997 Jan;34(1):64-9
pubmed: 9025164
Blood. 1982 Feb;59(2):447-51
pubmed: 7055650
Int J Hematol. 2022 Feb;115(2):198-207
pubmed: 34773575
Blood. 2014 Jun 19;123(25):3951-62
pubmed: 24778155
JCI Insight. 2022 Apr 22;7(8):
pubmed: 35259128
Blood Adv. 2020 Oct 27;4(20):5118-5132
pubmed: 33085758

Auteurs

Daniel Ivanov (D)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Jelena D Milosevic Feenstra (JD)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Irina Sadovnik (I)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Harald Herrmann (H)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria.

Barbara Peter (B)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Michael Willmann (M)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department for Companion Animals, Clinical Unit for Internal Medicine, University of Veterinary Medicine Vienna, Vienna, Austria.

Georg Greiner (G)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Ihr Labor, Medical Diagnostic Laboratories, Vienna, Austria.

Katharina Slavnitsch (K)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Institute of in vivo and in vitro Models, University of Veterinary Medicine Vienna, Vienna, Austria.

Emir Hadzijusufovic (E)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department for Companion Animals, Clinical Unit for Internal Medicine, University of Veterinary Medicine Vienna, Vienna, Austria.

Thomas Rülicke (T)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria.

Maik Dahlhoff (M)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Institute of in vivo and in vitro Models, University of Veterinary Medicine Vienna, Vienna, Austria.

Gregor Hoermann (G)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
MLL Munich Leukemia Laboratory, Munich, Germany.

Sigrid Machherndl-Spandl (S)

Hospital Ordensklinikum Elisabethinen Linz, Linz, Austria.
Johannes Kepler University, Medical Faculty, Linz, Austria.

Gregor Eisenwort (G)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, Vienna, Austria.

Michael Fillitz (M)

Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, Vienna, Austria.

Thamer Sliwa (T)

Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, Vienna, Austria.

Maria-Theresa Krauth (MT)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Peter Bettelheim (P)

Hospital Ordensklinikum Elisabethinen Linz, Linz, Austria.

Wolfgang R Sperr (WR)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Elisabeth Koller (E)

Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, Vienna, Austria.

Michael Pfeilstöcker (M)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, Vienna, Austria.

Heinz Gisslinger (H)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.

Felix Keil (F)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, Vienna, Austria.

Robert Kralovics (R)

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Peter Valent (P)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH